



Can Digenic, Tri-Allelic Inheritance of Variants in *STAR* and *CYP11A1* Give Rise to Primary Adrenal Insufficiency? A Case Report

Naseer Ali^{1*}, Avinaash Vickram Maharaj², Federica Buonocore³, John C. Achermann³ and Louise A. Metherell^{2*}

OPEN ACCESS

Edited by:

Amit V. Pandey,
University of Bern, Switzerland

Reviewed by:

Tulay Guran,
Marmara University, Turkey
Maki Fukami,
National Center for Child Health and
Development (NCCHD), Japan
Núria Camats,
Vall d'Hebron Research Institute
(VHIR), Spain

*Correspondence:

Naseer Ali
naseerpuli@yahoo.co.uk
Louise A. Metherell
l.a.metherell@qmul.ac.uk

Specialty section:

This article was submitted to
Pediatric Endocrinology,
a section of the journal
Frontiers in Endocrinology

Received: 22 January 2022

Accepted: 21 February 2022

Published: 28 March 2022

Citation:

Ali N, Maharaj AV, Buonocore F,
Achermann JC and Metherell LA
(2022) Can Digenic, Tri-Allelic
Inheritance of Variants in *STAR* and
CYP11A1 Give Rise to Primary Adrenal
Insufficiency? A Case Report.
Front. Endocrinol. 13:860055.
doi: 10.3389/fendo.2022.860055

¹ Department of Endocrinology and Metabolism, Meitra Hospital, Calicut, India, ² Centre for Endocrinology, William Harvey Research Institute, Queen Mary, University of London, London, United Kingdom, ³ Genetics & Genomic Medicine, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom

An eight-year old South Asian boy presenting with progressive hyperpigmentation was found to have primary adrenal insufficiency (PAI) in the form of isolated glucocorticoid deficiency. Follow up of this boy for nine years, until the age of 17 years showed normal pubertal onset and progression. Molecular evaluation, by targeted next generation sequencing of candidate genes linked to PAI revealed changes in two genes that are intricately linked in the early stages of steroid biosynthesis: compound heterozygous variants in *STAR*, c.465+1G>A and p.(E99K), plus a heterozygous rs6161 change in *CYP11A1*. No variants in other known causal genes were detected. The proband's mother was heterozygous for the c.465+1G>A *STAR* and rs6161 *CYP11A1* variants, while the father was homozygous for the p.(E99K) alteration in *STAR* but wild-type for *CYP11A1*. Both parents had normal adrenal cortical function as revealed by short Synacthen tests. The *STAR* variant c.465+1G>A will lead to abnormal splicing of exon 4 in mRNA and the addition of the p.(E99K) variant, predicted damaging by SIFT and CADD, may be sufficient to cause PAI but this is by no means certain given that the unaffected father is homozygous for the latter change. The rs6161 *CYP11A1* variant [c.940G>A, p.(E314K)] has recently been demonstrated to cause PAI in conjunction with a severe rare disruptive change on the other allele, however sequencing of the coding region of *CYP11A1* revealed no further changes in this subject. We wondered whether the phenotype of isolated glucocorticoid deficiency had arisen in this child due to tri-allelic inheritance of a heterozygous *CYP11A1* change along with the two *STAR* variants each of which contribute a partial loss-of-function burden that, when combined, is sufficient to cause PAI or if the loss-of-function c.465+1G>A combined with the presumed partial loss-of-function p.(E99K) in *STAR* could be causative.

Keywords: primary adrenal insufficiency, isolated glucocorticoid deficiency, *STAR*, *CYP11A1* (P450_{scc}), puberty

INTRODUCTION

Congenital primary adrenal insufficiency (PAI) in children is usually inherited as one of numerous monogenic disorders, with a molecular diagnosis being made in more than 90% of individuals (1–3). Principal causes include congenital adrenal hyperplasia (CAH), X-linked congenital adrenal hypoplasia (AHC), familial glucocorticoid deficiency (FGD) caused by adrenal cortical unresponsiveness to ACTH, adrenoleukodystrophy (ALD) and triple A syndrome (Allgrove syndrome) (1, 2). More recently, next generation sequencing (NGS) of patients with PAI has identified mutations in genes linked to altered redox potential, impaired oxidoreductase activity and sphingolipid metabolism, which include minichromosome maintenance 4 (*MCM4*), nicotinamide nucleotide transhydrogenase (*NNT*), thioredoxin reductase 2 (*TXNRD2*) and sphingosine 1-phosphate lyase (*SGPL1*) (4–7). Reaching a specific diagnosis can have implications for management and counselling. The genetic causes of PAI and their spectrum of disease have been reviewed recently (2, 3, 8).

FGD usually presents with isolated glucocorticoid deficiency with minimal or no mineralocorticoid deficiency. Inactivating mutations of the type 2 melanocortin receptor gene (*MC2R*) were the first genetic cause to be associated with FGD (FGD 1) (9, 10). Later, mutations in melanocortin 2 receptor accessory protein (*MRAP*) were also found to be causative (FGD2) (10–12). Together pathogenic variants in these genes only account for less than half of all cases of FGD.

Although mutations in steroidogenic acute regulator protein (*STAR*) have classically been associated with congenital lipoid adrenal hyperplasia, characterized by severe deficiency of both glucocorticoids and mineralocorticoids and no androgenization of 46,XY fetuses (13), partial loss-of-function variants in *STAR* are increasingly reported in patients diagnosed with FGD who presented with later onset, milder disease, and apparently normal gonadal function (14–16). *CYP11A1* encodes the P450 side chain cleavage enzyme (P450_{sc}) crucial in early steroidogenesis and, similar to *STAR*, classical *CYP11A1* mutations (resulting in disruption of the enzyme, P450_{sc}) also cause severe deficiency of both glucocorticoids and mineralocorticoids with no androgenization of 46,XY fetuses. Recently, certain mutations in *CYP11A1* have also been found in patients with milder phenotypes indistinguishable from FGD (17, 18); indeed, several studies have reported patients with the combination of a rs6161 (c.940G>A) variant that affects splicing, together with a severe loss-of-function change on the other allele as a cause of PAI presenting in childhood, but with normal or only mildly disrupted gonadal function (18). Taken together with the emerging experience from non-classic congenital lipoid adrenal hyperplasia due to *STAR* defects, these reports highlight a relation between enzyme function and phenotype and suggest that human adrenal function is more sensitive to partial disruption of *STAR* and *CYP11A1* than gonadal (testis) function.

Here we report long-term follow up of a boy with PAI presenting as isolated glucocorticoid deficiency possibly due to tri-allelic inheritance of variants in *STAR* and *CYP11A1*.

CASE REPORT

A boy born to non-consanguineous South Asian parents presented at the age of eight years with a history of progressive hyperpigmentation since early childhood. There was no prior history of electrolyte disturbances or evidence of adrenal crisis and family history was unremarkable for adrenal insufficiency. Additionally, screening for tuberculosis was negative. On examination, height was 124.5 cm (-0.6 SDS), target height 166 cm (-1.5 SDS) and weight 21 kg (-1.5 SDS). He had male external genitalia with no hypospadias, testicular volume of 2 ml bilaterally and absent pubic or axillary hair (Tanner stage 1). Blood pressure was 98 mmHg systolic and 66 mmHg diastolic. Hyperpigmentation of the skin was evident. There were no features suggestive of neurodegeneration, alacrima or achalasia, or other systemic features of note.

Serum biochemistry obtained at 8 years of age is presented in **Table 1**. His 8AM serum cortisol was within the lower normal range but was inappropriately low given the massively elevated ACTH. CT scan showed bilateral small adrenal glands. The patient was treated with oral hydrocortisone (7mcg/m²/day) which led to significant improvement in general well-being and partial improvement in hyperpigmentation. Neither parent manifested signs or symptoms of adrenal insufficiency and both had a normal cortisol response to short standard Synacthen tests (father, 49 years of age, post Synacthen cortisol 28.4 mcg/dL; mother, 43 years of age, post Synacthen cortisol 25.9 mcg/dL; with a post Synacthen cortisol > 20 mcg/dl considered as an adequate response).

After 5 years of follow up (at age 13), the proband's testicular volume was 6 ml bilaterally, pubic hair stage Tanner P1, and his height was 142 cm (-1.85 SDS), indicating age appropriate physiological onset of puberty. On examination at the age of 16 years, he had progressed through puberty; his height was 167.5 cm (-0.80 SDS), weight 52.6 kg (-0.92 SDS), blood pressure 106/60 mmHg. His testicular volume was 20 ml on both sides, pubic hair tanner stage P3. His morning serum testosterone level was 6.98 ng/mL (normal adult range, 2.3 - 9.5 ng/mL), and serum luteinizing hormone (LH) (2.73 IU/mL), and follicle-stimulating hormone (4.71 IU/mL) were normal. Further follow up at the age of 17 years confirmed a testicular volume of 20 ml on both sides, and showed progressive hair growth with pubic hair Tanner stage 5, and axillary hair present. His height was 170.5cm (-0.66 SDS). He had adequate height gain during puberty, so that his height SDS

TABLE 1 | Biochemical investigations at initial presentation at 8 years of age.


	Value	Reference range
Serum Sodium	138 mEq/L	135-145 mEq/L
Serum Potassium	4.4 mEq/L	3.5-5 mEq/L
Serum Cortisol (8AM)	6 mcg/dL	6-23 mcg/dL
Plasma ACTH (Adrenocorticotrophic hormone)	>2000 pg/mL	5-50 pg/mL
Serum DHEAS (Dehydroepiandrosterone Sulphate)	5.7 mcg/dL	23 - 209 mcg/dL
Plasma Renin activity	9.63 ng/mL/Hour	1.9- 5.2 ng/mL/Hour
Plasma Aldosterone concentration	121.8 pg/mL	12- 340 pg/mL

improved by the age of 17 years. He has a younger brother (10 years of age), who is asymptomatic and not hyperpigmented, and did not consent for hormonal or molecular testing.

Molecular Analysis

The proband was further evaluated for putative pathogenic variants in causal FGD genes and no variants were found in *MC2R* and *MRAP*. Further sequencing was performed on a HaloPlex targeted NGS panel (19) enabling concomitant detection of any variants in genes associated with PAI. Analysis showed that the proband had two heterozygous variants in *STAR*: chromosome 8:38003806C>T; c.465+1G>A and 8:38005729C>T; c.295G>A (rs903915397); p.(E99K) (GRCh37) (Figures 1A, B). Neither change has been previously reported in association with PAI and both are extremely rare. The c.465+1G>A change is not present in the gnomAD variant database, and the p.(E99K) change is very rare with only one heterozygous individual identified in gnomAD (minor allele frequency of 0.00003267 in South Asians). The c.465+1G>A

variant was inherited from the boy's mother, and is a canonical splice site mutation at the junction of exon 4 and intron 4. This variant alters the canonical donor splice site of intron 4 and is likely to lead to the skipping of exon 4 with the predicted consequence for the protein being an in-frame deletion of 56 amino acids (p.103_155del). The other *STAR* variant, c.295G>A; p.(E99K) is predicted to be damaging by SIFT (score 0.01) and CADD (score 27.5). His father who is homozygous for this variant, did not manifest an adrenal phenotype suggesting at least some residual function. The patient also inherited a heterozygous change, rs6161, in *CYP11A1* [c.940G>A, p.(E314K)] from his mother (Figures 1A, B), which was recently shown to result in partially defective splicing thereby producing a non-functional protein (18, 20). A second variant in *CYP11A1* was not identified. No other variants in genes on the HaloPlex array and known to cause adrenal insufficiency were uncovered by this analysis. This combination of findings raises the possibility that a non-classical congenital (lipoid) adrenal hyperplasia is the cause of isolated glucocorticoid deficiency in



this patient due to combined digenic, tri-allelic inheritance of two *STAR* mutations and the rs6161 *CYP11A1* variant.

DISCUSSION

This case describes the follow up of a boy with PAI, presenting as isolated glucocorticoid deficiency with small adrenals, possibly due to tri-allelic inheritance of two *STAR* mutations and the rs6161 *CYP11A1* variant. Although classically individuals with *STAR* mutations reportedly have large lipid laden adrenal glands in early life, there are reports of individuals with small adrenals, which may sometimes be due to the longer term effects of adrenal damage (21–23). In non-classic congenital lipoid adrenal hyperplasia, due to partial loss-of-function of *STAR*, the picture is mixed with both normal sized and hypoplastic adrenals described (14, 16, 24). For classic, loss-of-function mutations in *CYP11A1* large adrenal glands have not been described, but more often small or absent adrenals are noted (25) and - similar to *STAR* - partial loss-of-function variants of P450scc are associated with normal or small but never enlarged adrenal glands (18, 26, 27). Hence, whilst enlarged adrenals could have indicated a complete loss-of-function of *STAR*, normal or even small sized adrenals cannot rule out *STAR* or *CYP11A1* defects and give us no clue here to the underlying cause.

STAR mutations usually give rise to congenital lipoid adrenal hyperplasia but partial loss-of-function variants can present with an FGD-like phenotype of isolated glucocorticoid deficiency. Indeed, Baker et al. (16) described three FGD phenotype patients with *STAR* p.(V187M) and p.(R188C) mutations. Structural and functional analysis of these mutants revealed that they retained greater than 20% cholesterol binding activity. This residual activity may be the reason for the mild phenotype in these patients. Other studies also demonstrated that certain mutations in *STAR* [p.(R192C) and p.(R188C)] can present with a phenotype similar to that of FGD (13). In our patient, the *STAR* variant c.465+1G>A is predicted to lead to the skipping of exon 4 of the transcript with consequent in-frame deletion of 56 amino acids (p.103_155del) in the protein. This variant is likely to be loss-of-function. The second *STAR* variant p.(E99K) is predicted to be damaging, however the father of the patient was homozygous for this variant and did not manifest disease, suggesting only partial loss-of-function. Classical *CYP11A1* mutations also cause severe deficiency of both glucocorticoids and mineralocorticoids and no androgenization of 46,XY fetuses. Partial loss-of-function variants in *CYP11A1* can also give rise to a mild phenotype of a predominant FGD phenotype, with variable mineralocorticoid deficiency and often preserved testicular function (17). Indeed, the *CYP11A1* rs6161 variant found in our patient, which was initially considered to be benign and has a minor allele frequency in gnomAD of 0.002561 (0.001592 in South Asians), has recently been found to cause isolated glucocorticoid deficiency when combined with a severe loss-of-function *CYP11A1* defect, especially in patients from a European lineage (18, 20). This variant has been shown to have partial loss-of-function through mis-splicing and a reduced half-life of the protein P450scc (18, 28). We were unable to identify a second *CYP11A1* variant in the patient, suggesting a P450scc defect alone is not

causal. We hypothesize that the combination of a null allele (p.103_155del) with a partial loss-of-function allele [p.(E99K)] in *STAR* along with reduced function of P450scc due to the *CYP11A1* variant results in the phenotype; in effect, that sub-optimal function of the *STAR* protein, with biallelic inheritance of the two variants, alongside haploinsufficiency of p450scc side chain cleavage (*CYP11A1*) can be enough to reduce steroidogenic output such that the patient has late onset glucocorticoid deficiency but preserved mineralocorticoid and gonadal steroid production. This would be akin to the situation seen with non-classical congenital lipoid adrenal hyperplasia due to *STAR* variants p.(R188C) & p.(R192C) (14, 16) and non-classic P450scc deficiency due to mutations such as p.(R451W), p.(L222P), c.940G>A (rs6161) & p.(A269V) (26, 27, 29).

This young man appeared to progress through puberty. Individuals with partial defects in P450scc can sometimes later develop abnormal germ cell function associated with FSH elevation and oligozoospermia and impaired sperm motility and development of testicular adrenal rest tumours (30). Similarly, men with partial loss-of-function variants in *STAR* often progress through normal puberty, but can later show signs of gonadal dysfunction (14). Even though our patient has progressed through puberty normally, he needs to be monitored for later development of gonadal dysfunction and possible reduction in other adrenocortical hormones including mineralocorticoids, highlighting the importance of making a specific diagnosis in individuals with PAI (31).

Limitations of the Study

In vitro functional studies to determine whether the combination of the three variants together reduce function to a level where steroidogenesis is not supported were not possible. To try and recapitulate even the effects of one variant in a transient or short-term cellular system only really gives a snapshot – hence trying to combine the effects of these variants in a biologically relevant system would be very challenging.

We cannot rule out the possibility that an, as yet, unidentified genetic cause of adrenal insufficiency is causative in this case but the finding of three variants in two known causal genes is persuasive that this could represent the first description of digenic, tri-allelic PAI.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

NA clinically and biochemically evaluated the patient and wrote the first draft of the article. LM conceptualized the article. LM and AM did the molecular analysis. FB and JA contributed to the molecular evaluation and concept of the article. All authors contributed to manuscript revision, read and approved the submitted version.

FUNDING

LM received the Medical Research Council UK Project Grant MR/K020455/1. JA is a Wellcome Trust Senior Research Fellow in Clinical Science (grants 098513/Z/12/Z and

209328/Z/17/Z) with research support from Great Ormond Street Hospital Children's Charity (grant V2518) and the National Institute for Health Research, Great Ormond Street Hospital Biomedical Research Centre (grant IS-BRC-1215-20012).

REFERENCES

- Kirkgoz T, Guran T. Primary Adrenal Insufficiency in Children: Diagnosis and Management. *Best Pract Res Clin Endocrinol Metab* (2018) 32:397–424. doi: 10.1016/j.beem.2018.05.010
- Buonocore F, McGlacken-Byrne SM, Del Valle I, Achermann JC. Current Insights Into Adrenal Insufficiency in the Newborn and Young Infant. *Front Pediatr* (2020) 8:619041. doi: 10.3389/fped.2020.619041
- Buonocore F, Maharaj A, Qamar Y, Koehler K, Suntharalingham JP, Chan LF, et al. Genetic Analysis of Pediatric Primary Adrenal Insufficiency of Unknown Etiology: 25 Years' Experience in the UK. *J Endocr Soc* (2021) 5(8):bvab086. doi: 10.1210/jendso/bvab086
- Gineau L, Cognet C, Kara N, Lach FP, Dunne J, Veturi U, et al. Partial MCM4 Deficiency in Patients With Growth Retardation, Adrenal Insufficiency, and Natural Killer Cell Deficiency. *J Clin Invest* (2012) 122:821–32. doi: 10.1172/JCI61014
- Meimaridou E, Kowalczyk J, Guasti L, Hughes CR, Wagner F, Frommolt P, et al. Mutations in NNT Encoding Nicotinamide Nucleotide Transhydrogenase Cause Familial Glucocorticoid Deficiency. *Nat Genet* (2012) 44:740–742. doi: 10.1038/ng.2299
- Prasad R, Chan LF, Hughes CR, Kaski JP, Kowalczyk JC, Savage MO, et al. Thioredoxin Reductase 2 (TXNRD2) Mutation Associated With Familial Glucocorticoid Deficiency (FGD). *J Clin Endocrinol Metab* (2014) 99:E1556–1563. doi: 10.1210/jc.2013-3844
- Prasad R, Hadjidemetriou I, Maharaj A, Meimaridou E, Buonocore F, Saleem M, et al. Sphingosine-1-Phosphate Lyase Mutations Cause Primary Adrenal Insufficiency and Steroid-Resistant Nephrotic Syndrome. *J Clin Invest* (2017) 127:942–53. doi: 10.1172/JCI90171
- Flück CE. Mechanisms in Endocrinology: Update on Pathogenesis of Primary Adrenal Insufficiency: Beyond Steroid Enzyme Deficiency and Autoimmune Adrenal Destruction. *Eur J Endocrinol* (2017) 177:3. doi: 10.1530/EJE-17-0128
- Cooray SN, Chan L, Metherell L, Storr H, Clark AJL. Adrenocorticotropin Resistance Syndromes. *Endocr Dev* (2008) 13:99–116. doi: 10.1159/000134828
- Chan LF, Clark AJL, Metherell LA. Familial Glucocorticoid Deficiency: Advances in the Molecular Understanding of ACTH Action. *Horm Res Paediatr* (2008) 69:75–82. doi: 10.1159/000111810
- Metherell LA, Chapple JP, Cooray S, David A, Becker C, Rüschenhoff F, et al. Mutations in MRAP, Encoding a New Interacting Partner of the ACTH Receptor, Cause Familial Glucocorticoid Deficiency Type 2. *Nat Genet* (2005) 37:166–70. doi: 10.1038/ng1501
- Génin E, Huebner A, Jaillard C, Faure A, Halaby G, Saka N, et al. Linkage of One Gene for Familial Glucocorticoid Deficiency Type 2 (FGD2) to Chromosome 8q and Further Evidence of Heterogeneity. *Hum Genet* (2002) 111:428–34. doi: 10.1007/s00439-002-0806-3
- Stocco DM. Clinical Disorders Associated With Abnormal Cholesterol Transport: Mutations in the Steroidogenic Acute Regulatory Protein. *Mol Cell Endocrinol* (2002) 191:19–25. doi: 10.1016/s0303-7207(02)00048-5
- Metherell LA, Naville D, Halaby G, Begeot M, Huebner A, Nürnberg G, et al. Nonclassic Lipoid Congenital Adrenal Hyperplasia Masquerading as Familial Glucocorticoid Deficiency. *J Clin Endocrinol Metab* (2009) 94:3865–71. doi: 10.1210/jc.2009-0467
- Chen X, Baker BY, Abduljabbar MA, Miller WL. A Genetic Isolate of Congenital Lipoid Adrenal Hyperplasia With Atypical Clinical Findings. *J Clin Endocrinol Metab* (2005) 90:835–40. doi: 10.1210/jc.2004-1323
- Baker BY, Lin L, Kim CJ, Raza J, Smith CP, Miller WL, et al. Nonclassic Congenital Lipoid Adrenal Hyperplasia: A New Disorder of the Steroidogenic Acute Regulatory Protein With Very Late Presentation and Normal Male Genitalia. *J Clin Endocrinol Metab* (2006) 91:4781–5. doi: 10.1210/jc.2006-1565
- Tee MK, Abramssohn M, Loewenthal N, Harris M, Siwach S, Kaplinsky A, et al. Varied Clinical Presentations of Seven Patients With Mutations in CYP11A1 Encoding the Cholesterol Side-Chain Cleavage Enzyme, P450_{sc}. *J Clin Endocrinol Metab* (2013) 98:713–20. doi: 10.1210/jc.2012-2828
- Maharaj A, Buonocore F, Meimaridou E, Ruiz-Babot G, Guasti L, Peng HM, et al. Predicted Benign and Synonymous Variants in CYP11A1 Cause Primary Adrenal Insufficiency Through Missplicing. *J Endocr Soc* (2019) 3:201–21. doi: 10.1210/js.2018-00130
- Guran T, Buonocore F, Saka N, Ozbek MN, Aycan Z, Bereket A, et al. Rare Causes of Primary Adrenal Insufficiency: Genetic and Clinical Characterization of a Large Nationwide Cohort. *J Clin Endocrinol Metab* (2015) 101(1):284–92. doi: 10.1210/jc.2015-3250
- Goursaud C, Mallet D, Janin A, Menassa R, Tardy-Guidollet V, Russo G, et al. Aberrant Splicing is the Pathogenicity Mechanism of the P.Glu314Lys Variant in CYP11A1 Gene. *Front Endocrinol* (2018) 9:491. doi: 10.3389/fendo.2018.00491
- Bose HS, Sato S, Aisenberg J, Shalev SA, Matsuo N, Miller WL. Mutations in the Steroidogenic Acute Regulatory Protein (Star) in Six Patients With Congenital Lipoid Adrenal Hyperplasia. *J Clin Endocrinol Metab* (2000) 85(10):3636–9. doi: 10.1210/jcem.85.10.6896
- Gucev ZS, Tee MK, Chitayat D, Wherrett DK, Miller WL. Distinguishing Deficiencies in the Steroidogenic Acute Regulatory Protein and the Cholesterol Side Chain Cleavage Enzyme Causing Neonatal Adrenal Failure. *J Pediatr* (2013) 162(4):819–22. doi: 10.1016/j.jpeds.2012.10.012
- Zhao X, Su Z, Liu X, Song J, Gan Y, Wen P, et al. Long-Term Follow-Up in a Chinese Child With Congenital Lipoid Adrenal Hyperplasia Due to a Star Gene Mutation. *BMC Endocr Disord* (2018) 18(1):78. doi: 10.1186/s12902-018-0307-6
- Sahakitrungruang T, Soccio RE, Lang-Muritano M, Walker JM, Achermann JC, Miller WL. Clinical, Genetic, and Functional Characterization of Four Patients Carrying Partial Loss-of-Function Mutations in the Steroidogenic Acute Regulatory Protein (Star). *J Clin Endocrinol Metab* (2010) 95(7):3352–9. doi: 10.1210/jc.2010-0437
- Kim CJ, Lin L, Huang N, Quigley CA, Avruskin TW, Achermann JC, et al. Severe Combined Adrenal and Gonadal Deficiency Caused by Novel Mutations in the Cholesterol Side Chain Cleavage Enzyme, P450_{sc}. *J Clin Endocrinol Metab* (2008) 93(3):696–702. doi: 10.1210/jc.2007-2330
- Sahakitrungruang T, Tee MK, Blackett PR, Miller WL. Partial Defect in the Cholesterol Side-Chain Cleavage Enzyme P450_{sc} (CYP11A1) Resembling Nonclassic Congenital Lipoid Adrenal Hyperplasia. *J Clin Endocr Metab* (2011) 96:792–8. doi: 10.1210/jc.2010-1828
- Rubtsov P, Karmanov M, Sverdllova P, Spirin P, Tiulpakov A. A Novel Homozygous Mutation in CYP11A1 Gene is Associated With Late-Onset Adrenal Insufficiency and Hypospadias in a 46,XY Patient. *J Clin Endocrinol Metab* (2009) 94:936–9. doi: 10.1210/jc.2008-1118
- Kolli V, Kim H, Torky A, Lao Q, Tatsi C, Mallappa A, et al. Characterization of the CYP11A1 Nonsynonymous Variant P.E314K in Children Presenting With Adrenal Insufficiency. *J Clin Endocrinol Metab* (2019) 104(2):269–76. doi: 10.1210/jc.2018-01661
- Sarathi V, Nagalingam C. Normal Male External Genitalia do Not Rule Out CYP11A1 Deficiency. *BMJ Case Rep* (2019) 12(7):e228235. doi: 10.1136/bcr-2018-228235
- Kallali W, Gray E, Mehdi MZ, Lindsay R, Metherell LA, Buonocore F, et al. Long-Term Outcome of Partial P450 Side-Chain Cleavage Enzyme Deficiency

in Three Brothers: The Importance of Early Diagnosis. *Eur J Endocrinol* (2020) 182(3):K15–24. doi: 10.1530/EJE-19-0696

31. Kamrath C. Beyond the Adrenals: Organ Manifestations in Inherited Primary Adrenal Insufficiency in Children. *Eur J Endocrinol* (2020) 182(3):C9–C12. doi: 10.1530/EJE-19-0995

Author Disclaimer: The views expressed are those of the authors and not necessarily those of the National Health Service, National Institute for Health Research, or Department of Health.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ali, Maharaj, Buonocore, Achermann and Metherell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.